David Voderholzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Voderholzer has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alisdair Stevenson
Department of Biology, Institute of Biochemistry, ETH Zurich, Otto Stern Weg 3, 8093 Zurich, Switzerland
4 shared publications - Thomas C. T. Michaels
Department of Biology, Institute of Biochemistry, ETH Zurich, Zurich, Switzerland
3 shared publications - Alexander Kai Buell
Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark
2 shared publications - Georg Meisl
Yusuf Hamied Department of Chemistry University of Cambridge Cambridge UK
2 shared publications - Michele Vendruscolo
Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK
2 shared publications - Tuomas P. J. Knowles
Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK
2 shared publications
Latest Publications
- Open Access
- 14 October 2025
- Published by AIP Publishing in The Journal of Chemical Physics
- Vol. 163 (14)
Self-consistent analytical solutions to the kinetics of lipid-induced protein aggregation
The aggregation of proteins into amyloid fibrils is a hallmark of several neurodegenerative disorders, including Parkinson’s disease. A growing body of experimental evidence highlights the significant role lipid membranes play in modulating this aggregation process, particularly for proteins such as α-synuclein. Despite this, there has been a lack of quantitative theoretical frameworks capable of describing the kinetics of lipid-induced protein aggregation. In this work, we develop an analytical theoretical model that explicitly incorporates lipid-mediated interactions into the aggregation kinetics. By formulating rate equations in terms of lipid surface coverage and applying a fixed-point analysis, we derive self-consistent solutions for the full timecourse of aggregation. Our model captures both one-step and two-step nucleation mechanisms and enables the prediction of key kinetic observables, including half-times and maximal growth rates. These results provide a quantitative foundation for interpreting experimental data and offer new mechanistic insights into how lipids influence the self-assembly of amyloidogenic proteins.
- 14 October 2025
- Published by AIP Publishing in The Journal of Chemical Physics
- Vol. 163 (14)
Open AccessSelf-consistent analytical solutions to the kinetics of lipid-induced protein aggregation
The aggregation of proteins into amyloid fibrils is a hallmark of several neurodegenerative disorders, including Parkinson’s disease. A growing body of experimental evidence highlights the significant role lipid membranes play in modulating this aggregation process, particularly for proteins such as α-synuclein. Despite this, there has been a lack of quantitative theoretical frameworks capable of describing the kinetics of lipid-induced protein aggregation. In this work, we develop an analytical theoretical model that explicitly incorporates lipid-mediated interactions into the aggregation kinetics. By formulating rate equations in terms of lipid surface coverage and applying a fixed-point analysis, we derive self-consistent solutions for the full timecourse of aggregation. Our model captures both one-step and two-step nucleation mechanisms and enables the prediction of key kinetic observables, including half-times and maximal growth rates. These results provide a quantitative foundation for interpreting experimental data and offer new mechanistic insights into how lipids influence the self-assembly of amyloidogenic proteins.
- Open Access
Self-consistent analytical solutions to the kinetics of lipid-induced protein aggregation
The aggregation of proteins into amyloid fibrils is a hallmark of several neurodegenerative disorders, including Parkinson’s disease. A growing body of experimental evidence highlights the significant role lipid membranes play in modulating this aggregation process, particularly for proteins such as α -synuclein. Despite this, there has been a lack of quantitative theoretical frameworks capable of describing the kinetics of lipid-induced protein aggregation. In this work, we develop an analytical model that explicitly incorporates lipid-mediated interactions into the aggregation kinetics. By formulating rate equations in terms of lipid surface coverage and applying a fixed-point analysis, we derive self-consistent solutions for the full timecourse of aggregation. Our model captures both one-step and two-step nucleation mechanisms and enables the prediction of key kinetic observables, including half-times and maximal growth rates. These results provide a quantitative foundation for interpreting experimental data and offer new mechanistic insights into how lipids influence the self-assembly of amyloidogenic proteins.
Open AccessSelf-consistent analytical solutions to the kinetics of lipid-induced protein aggregation
The aggregation of proteins into amyloid fibrils is a hallmark of several neurodegenerative disorders, including Parkinson’s disease. A growing body of experimental evidence highlights the significant role lipid membranes play in modulating this aggregation process, particularly for proteins such as α -synuclein. Despite this, there has been a lack of quantitative theoretical frameworks capable of describing the kinetics of lipid-induced protein aggregation. In this work, we develop an analytical model that explicitly incorporates lipid-mediated interactions into the aggregation kinetics. By formulating rate equations in terms of lipid surface coverage and applying a fixed-point analysis, we derive self-consistent solutions for the full timecourse of aggregation. Our model captures both one-step and two-step nucleation mechanisms and enables the prediction of key kinetic observables, including half-times and maximal growth rates. These results provide a quantitative foundation for interpreting experimental data and offer new mechanistic insights into how lipids influence the self-assembly of amyloidogenic proteins.
- Open Access
- 25 June 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (26)
Global kinetic model of lipid-induced α -synuclein aggregation and its inhibition by small molecules
The aggregation of α -synuclein into amyloid fibrils is a hallmark of Parkinson’s disease. This process has been shown to directly involve interactions between proteins and lipid surfaces when the latter are present. Despite this importance, the molecular mechanisms of lipid-induced amyloid aggregation have remained largely elusive. Here, we present a global kinetic model to describe lipid-induced amyloid aggregation of α -synuclein. Using this framework, we find that α -synuclein fibrils form via a two-step primary nucleation mechanism and that lipid molecules are directly involved in both the nucleation and fibril elongation steps, giving rise to lipid–protein coaggregates. To illustrate the applicability of this kinetic approach to drug discovery, we identify the mechanism of action of squalamine, a known inhibitor of lipid-induced α -synuclein aggregation, revealing that this small molecule reduces the rate of lipid-dependent primary nucleation. Our work will likely guide the rational design of α -synuclein aggregation inhibitors.
- 25 June 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (26)
Open AccessGlobal kinetic model of lipid-induced α -synuclein aggregation and its inhibition by small molecules
The aggregation of α -synuclein into amyloid fibrils is a hallmark of Parkinson’s disease. This process has been shown to directly involve interactions between proteins and lipid surfaces when the latter are present. Despite this importance, the molecular mechanisms of lipid-induced amyloid aggregation have remained largely elusive. Here, we present a global kinetic model to describe lipid-induced amyloid aggregation of α -synuclein. Using this framework, we find that α -synuclein fibrils form via a two-step primary nucleation mechanism and that lipid molecules are directly involved in both the nucleation and fibril elongation steps, giving rise to lipid–protein coaggregates. To illustrate the applicability of this kinetic approach to drug discovery, we identify the mechanism of action of squalamine, a known inhibitor of lipid-induced α -synuclein aggregation, revealing that this small molecule reduces the rate of lipid-dependent primary nucleation. Our work will likely guide the rational design of α -synuclein aggregation inhibitors.
- Open Access
- 18 November 2024
- Published by American Physical Society (APS) in Physical Review Research
- Vol. 6 (4)
Nonrelativistic ferromagnetotriakontadipolar order and spin splitting in hematite
We show that hematite, α − Fe 2 O 3 , below its Morin transition, has a ferroic ordering of rank-5 magnetic triakontadipoles on the Fe ions. In the absence of spin-orbit coupling, these are the lowest-order ferroically aligned magnetic multipoles, and they give rise to the g -wave nonrelativistic spin splitting in hematite. We find that the ferroically ordered magnetic triakontadipoles result from the simultaneous antiferroic ordering of the charge hexadecapoles and the magnetic dipoles, providing a route to manipulating the magnitude and the sign of the magnetic triakontadipoles as well as the spin splitting. Furthermore, we find that both the ferroic ordering of the magnetic triakontadipoles and many of the spin-split features persist in the weak ferromagnetic phase above the Morin transition temperature. Published by the American Physical Society 2024
- 18 November 2024
- Published by American Physical Society (APS) in Physical Review Research
- Vol. 6 (4)
Open AccessNonrelativistic ferromagnetotriakontadipolar order and spin splitting in hematite
We show that hematite, α − Fe 2 O 3 , below its Morin transition, has a ferroic ordering of rank-5 magnetic triakontadipoles on the Fe ions. In the absence of spin-orbit coupling, these are the lowest-order ferroically aligned magnetic multipoles, and they give rise to the g -wave nonrelativistic spin splitting in hematite. We find that the ferroically ordered magnetic triakontadipoles result from the simultaneous antiferroic ordering of the charge hexadecapoles and the magnetic dipoles, providing a route to manipulating the magnitude and the sign of the magnetic triakontadipoles as well as the spin splitting. Furthermore, we find that both the ferroic ordering of the magnetic triakontadipoles and many of the spin-split features persist in the weak ferromagnetic phase above the Morin transition temperature. Published by the American Physical Society 2024
- Open Access
Global kinetic model of lipid-induced α -synuclein aggregation and its inhibition by small molecules
The aggregation of α -synuclein into amyloid fibrils is a hallmark of Parkinson’s disease. This process has been shown to directly involve interactions between proteins and lipid surfaces when the latter are present. Despite this importance, the molecular mechanisms of lipid-induced amyloid aggregation have remained largely elusive. Here, we present a global kinetic model to describe lipid-induced amyloid aggregation of α -synuclein. Using this framework we find that α -synuclein fibrils form via a two-step primary nucleation mechanism and that lipid molecules are directly involved in both the nucleation and fibril elongation steps, giving rise to lipid-protein coaggregates. To illustrate the applicability of this kinetic approach to drug discovery, we identify the mechanism of action of squalamine, a known inhibitor of α-synuclein aggregation, finding that this small molecule reduces the rate of lipid-dependent primary nucleation. Our work will likely guide the rational design of α -synuclein aggregation inhibitors. Significance Statement: Amyloid aggregation is a hallmark of a diverse range of diseases including Parkinson’s Disease, where the protein α -synuclein is a major con-stituent of proteinaceous deposits found in patients. It is well established that interactions between α -synuclein and lipids modulate aggregation. However, the molecular mechanisms driving this lipid-induced aggregation have remained largely elusive, which has frustrated so far the discovery of drugs that prevent lipid-induced aggregation. In this work, we present the first global kinetic model describing lipid-induced aggregation and by integrating this theoretical framework with in vitro experimental data of lipid-induced α -synuclein aggregation, we reveal the role of lipid membranes in the aggregation process and uncover the mechanism by which small molecule inhibitors interfere with this process.
Open AccessGlobal kinetic model of lipid-induced α -synuclein aggregation and its inhibition by small molecules
The aggregation of α -synuclein into amyloid fibrils is a hallmark of Parkinson’s disease. This process has been shown to directly involve interactions between proteins and lipid surfaces when the latter are present. Despite this importance, the molecular mechanisms of lipid-induced amyloid aggregation have remained largely elusive. Here, we present a global kinetic model to describe lipid-induced amyloid aggregation of α -synuclein. Using this framework we find that α -synuclein fibrils form via a two-step primary nucleation mechanism and that lipid molecules are directly involved in both the nucleation and fibril elongation steps, giving rise to lipid-protein coaggregates. To illustrate the applicability of this kinetic approach to drug discovery, we identify the mechanism of action of squalamine, a known inhibitor of α-synuclein aggregation, finding that this small molecule reduces the rate of lipid-dependent primary nucleation. Our work will likely guide the rational design of α -synuclein aggregation inhibitors. Significance Statement: Amyloid aggregation is a hallmark of a diverse range of diseases including Parkinson’s Disease, where the protein α -synuclein is a major con-stituent of proteinaceous deposits found in patients. It is well established that interactions between α -synuclein and lipids modulate aggregation. However, the molecular mechanisms driving this lipid-induced aggregation have remained largely elusive, which has frustrated so far the discovery of drugs that prevent lipid-induced aggregation. In this work, we present the first global kinetic model describing lipid-induced aggregation and by integrating this theoretical framework with in vitro experimental data of lipid-induced α -synuclein aggregation, we reveal the role of lipid membranes in the aggregation process and uncover the mechanism by which small molecule inhibitors interfere with this process.